STAT3-siRNA induced B16.F10 melanoma cell death: more association with VEGF downregulation than p-STAT3 knockdown

Publication date: Available online 30 May 2018Source: Saudi Pharmaceutical JournalAuthor(s): Aws AlshamsanAbstractSTAT3 knockdown by small interfering RNA (siRNA) has been described to inhibit carcinogenic growth in various types of tumors. Earlier we have reported delivery of siRNA by oleic acid- and stearic acid-modified-polyethylenimine and enhancement of silencing of STAT3 by small interfering RNA (siRNA) in B16.F10 melanoma cell lines and consequent tumor suppression. Present investigation mainly focused on the downstream events involved in B16.F10 melanoma cell death and consequent tumor suppression following knockdown of p-STAT3 by siRNA. Lipid-substituted polyethylenimine (PEI)-p-STAT3-siRNA were prepared and characterized by measuring its N/P ratio, zeta potential, size, association and dissociation with siRNA. B16.F10 melanoma cells were treated with six different concentrations of PEI-p-STAT3-siRNA (200, 100, 50, 25, 12.5 and 6.25 nM). Downregulation of p-STAT3 and VEGF were studied using western blot and ELISA in association with the melanoma cell death. PEI-p-STAT3-siRNA hydrodynamic diameter ranged from 110 to 270 nm. PEI assisted p-STAT3-siRNA delivery exhibited increased uptake by B16.F10, when analyzed by fluorescent and confocal microscopy along with flowcytometry. It induced concentration-dependent knockdown of the p-STAT3 that also downregulated VEGF expression in similar fashion and induced B16.F10 cell death. Higher concentrations of p-STAT3-siRNA ap...
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research

Related Links:

In conclusion, this study makes clear that lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells through up-regulating c-myc expression via enhancing its combination with TGF2BP1 protein. Overall, our study illustrates that lncRNA THOR/c-myc molecular cascade might be another potent target for retinoblastoma treatment.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
AbstractEfforts to prevent melanoma, especially for those at elevated risk for the disease, should ideally begin during childhood. However, there are few preventive interventions targeting children who are at higher risk for melanoma due to a family history of the disease. Further, there are no educational interventions that aim to help these at-risk children understand their risk for melanoma and the ways in which preventive behaviors, such as sun protection, can mitigate their risk. The current paper describes a multidisciplinary team ’s process for creating a developmentally appropriate educational intervention ab...
Source: Journal of Cancer Education - Category: Cancer & Oncology Source Type: research
Condition:   Intervention:   Drug: omaveloxolone Sponsor:   Reata Pharmaceuticals, Inc. Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions“InterPreT Cancer Survival” is presented as an educational tool which engages the user through interactive features to improve the understanding of commonly reported cancer survival statistics. The tool has received positive feedback from a Cancer Research UK patient sounding board and there are further plans to incorporate more disease characteristics, e.g. stage.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
ConclusionsWe found some evidence that higher intake of folate from food only was associated with a modest increased risk of cutaneous melanoma. However, since other factors related to dietary folate intake may account for the observed association, our findings warrant further investigation.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
I took our cat, Peekaboo, to the vet two days ago, around lunchtime. When her new CAT scan results came in, my vet told me that, even though the melanoma had spread a bit in the past two weeks, the cancer hadn’t gone into the jawbone yet. She recommended that we do the surgery. After asking a few obvious but almost-impossible-to-answer questions (will the surgery PROLONG HER LIFE without impacting her QUALITY OF LIFE, blablabla), I called Stefano, and we both agreed it was our only choice at this point, even though there really aren’t any guarantees: this sort of cancer is very aggressive, so it may come back a...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll cat surgery feline oral cancer feline oral melanoma Source Type: blogs
Melanoma brain metastases (MBM) often cause morbidity and mortality for stage IV melanoma patients. An ongoing randomised phase III trial (NCT01503827 – WBRT-Mel) evaluates the role of adjuvant whole brain rad...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Interleukin-like EMT inducer (ILEI, FAM3C) is a secreted factor that contributes to the epithelial-to-mesenchymal transition (EMT), a cell-biological process that confers metastatic properties to a tumor cell. However, very little is known about how ILEI is regulated. Here we demonstrate that ILEI is an in vivo regulator of melanoma invasiveness and is transcriptionally up-regulated by the upstream stimulatory factor-1 (USF-1), an E-box–binding, basic-helix-loop-helix family transcription factor. shRNA-mediated knockdown of ILEI in melanoma cell lines attenuated lung colonization but not primary tumor formation. We a...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Gene Regulation Source Type: research
We have previously shown that Notch1 plays a critical role in modulating melanoma tumor cell growth and survival. Here we show that Notch1 also contributes to an immune-suppressive tumor microenvironment (TME). Notch1 inhibition reduces immune suppressive cells (i.e. MDSCs and Tregs) while allowing the recruitment of functional CD8(+) T cells, leading to a decrease in the Tregs/CD8(+) ratio, a key parameter in assessing positive responses to immune-checkpoint inhibitors. Inhibition of Notch1 improves the antitumor activity of nivolumab and ipilimumab, particularly when given in combination.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research
Recent clinical trials demonstrated the efficacy of novel biologics as metastatic melanoma treatments. These drugs include ipilimumab, an antibody that targets CTLA4 as well as pembrolizumab and nivolumab, antibodies that target programmed death 1 (PD-1). Following approval of ipilimumab and nivolumab as effective agents for adjuvant therapy, Eggermont and colleagues initiated a study to compare pembrolizumab treatment with matching placebo as adjuvant therapy for patients with  resected, high-risk stage III melanoma.
Source: Journal of Investigative Dermatology - Category: Dermatology Tags: Editorial Source Type: research
More News: Cancer & Oncology | Melanoma | Middle East Health | Saudi Arabia Health | Skin Cancer